glp-1 agonists vision loss blindness The Impact of Receptor on Ocular Disease Do GLP-1 Medications Cause Eye

What's your research focused on

2026;330:C265C278

Directions Recommended dose: 1 capsule per day

ENT-01 ( squalamine phosphate ) inhibits -synuclein aggregation in the gastrointestinal tract and significantly increased the number of complete spontaneous bowel movements per week after 25 days on ENT-01 treatment in a double-blind, placebo-controlled, phase 2b RCT in 150 participants with PD and constipation however at the expense of gastrointestinal AEs in up to one third of participants [166]

654 Of note, astrocyte-specific deletion of mutant huntingtin in mice globally expressing this gene eased disease symptoms and delayed its progression, indicating a role for astrocytes in the pathophysiology of the disease